- Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
-
Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H
- KMID: 2512101
- Intest Res.
- 2021 Jan;19(1):53-61.
- doi: 10.5217/ir.2019.09146
Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
-
Kobayashi T, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T
- KMID: 2521608
- Intest Res.
- 2021 Oct;19(4):448-460.
- doi: 10.5217/ir.2020.00026
Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
